Pages

Showing posts with label USA. Show all posts
Showing posts with label USA. Show all posts

Tuesday, 20 October 2020

The COVID-19 Documentary All Americans Need to See

 Totally Under Control delivers a damning—and essential—report card on the White House’s mismanagement of the pandemic.


This film feels shocking to watch in retrospect for its crisp frankness.NEON 

Given the ongoing nature of the pandemic, it may seem senseless to make a two-hour film that looks back on how the coronavirus ran rampant in the U.S. And yet, Totally Under Control—from the Oscar-winning writer-director Alex Gibney and his co-directors, Ophelia Harutyunyan and Suzanne Hillinger—not only documents the chaos of 2020 with clear-eyed precision, but also successfully argues for its own existence.

Filmed in secret over five months, Totally Under Control (streaming on Hulu) uses news footage and interviews with experts and government whistleblowers to show how the administration missed each opportunity to either stop the virus from arriving in the U.S. or prevent its spread. The filmmakers present these events in rapid, blow-by-blow succession, lending the doc an urgency that contrasts with the languid federal response to the pandemic. The result is a film that—unlike 76 Days, the moving and intimate documentary on the lockdown in Wuhan, China, made without talking heads—feels shocking to watch in retrospect for its crisp frankness. Viewers may have grown numb to the constant churn of distressing news and learned to stomach the administration’s failure to contain the virus. But Totally Under Control refuses to look away, and being reminded of how many warnings went unheeded is unnerving.

I forgot, for instance, that in February and March, cruise ships that couldn’t dock had been petri dishes that carried infected Americans while the administration dismissed the virus’s threat. I forgot that the Centers for Disease Control and Prevention once discouraged the general public from wearing masks, because health-care workers needed the limited supply. I also forgot that Nancy Messonnier, of the CDC, warned at the end of February that the virus would spread in the U.S., and days later, she stopped appearing in the White House’s briefings.

If Totally Under Control simply presented all of these facts as events on a timeline, it would have come off as a brutal but rote history lesson. Instead, Gibney and his co-directors make the scope of America’s failures clear by comparing America’s response with that of South Korea. The two first-world countries found their first cases on the same day in January, but only one managed to avoid shutdowns and an economic free fall. In a rather wistful interview, the South Korean doctor Kim Jin Yong speaks candidly about how much he admired America and the CDC. He points out that 90 percent of the medical textbooks in South Korea are American, and that America has paved the way for medical advances, including inventing the N95 face mask in the 1990s. So watching America flounder has been, he says bluntly, “so sad.”

Gibney and his collaborators don’t interview some of the major players of the pandemic, such as Anthony Fauci, but the ones they do—mostly whistleblowers, government officials, and health-care experts such as Yong, who sat down for the camera behind sheets of plastic—exude a palpable exhaustion and wariness. Some, such as Max Kennedy Jr., one of the volunteers on Jared Kushner’s slapdash team tasked with procuring ventilators and personal protective equipment, speak cathartically about the lack of leadership. Others sound and appear drained: Scott Becker, the CEO of the Association of Public Health Laboratories, chokes up while talking about his anxiety during the month when labs around the country couldn’t receive reliable COVID-testing kits.


Totally Under Control refuses to offer the viewer a soothing or satisfying conclusion, and instead demands action. (Neon)

But ultimately, health-care workers offer the strongest testimonies, perspectives the filmmakers juxtapose with the administration’s rosy updates. After an audio clip plays of the president declaring that the U.S. “wasn’t built to be shut down,” Taison Bell, the ICU director of the University of Virginia Medical Center, describes feeling helpless in the face of the disease. Francis Riedo, the medical director of Infectious Disease at EvergreenHealth in Seattle, talks of having one of his patients become the first American pandemic casualty, in a sound bite that plays after the president is shown celebrating zero COVID-related deaths in the U.S.


There are many moments like these. Totally Under Control—which takes its name from Trump’s own words—weaves in dozens of clips of the president’s constant downplaying of the virus. It couples his unfounded optimism with montages of people shouting at the essential workers who ask them to put on masks, and his boasts of American exceptionalism with footage of New York City’s weeks as the pandemic’s epicenter. It’s an ingenious move: The filmmakers condemn Trump’s leadership with his own statements, creating a call-and-response between the devastating reality and his wishful thinking. Gibney and his collaborators maintain that they don’t see the film as political, but instructive; they pushed to release the documentary before the presidential election in order to remind the public of the current administration's ineptitude.

Totally Under Control is unlikely to change minds; with a title and art that mocks the president, plus footage criticizing anti-maskers, there’s little chance that those who have refused to acknowledge the science of the pandemic will be interested in watching the film in the first place. Then again, it may seem illogical for anyone to press play on a documentary that looks back on the past 10 months and revisits how harrowing they’ve been. Even after the election, who would want to rewatch the worst moments of the worst year in recent history when all of it is still happening and the news is constantly mutating? What’s the point of having Americans revisit their trauma?

The filmmakers grapple with these questions when the timeline catches up to the present. Gibney’s previous documentaries—Going Clear, The Inventor—have offered neat takeaways about their subjects in their final minutes: Scientology is a harmful yet powerful entity; the downfall of Theranos’s founder, Elizabeth Holmes, embodies the dangers of Silicon Valley’s hubris. When it comes to what the administration’s coronavirus-response failures mean, however, Gibney can give only an unsettling, rather abrupt ending. “Our ability to reckon with the future will depend on how much we learn from our recent past,” he narrates. “Will we be ready to fix what’s already broken?”

But that’s what Totally Under Control does best—it refuses to offer the viewer a soothing or satisfying conclusion, and instead demands action. It denounces the president, but it also focuses on the responsibility of the American public to remain vigilant in preventing the spread of the virus, to fight the news-induced numbness, and to challenge those in power whose false promises can undermine the true reality of a crisis.

In the final seconds of the film, a title card reveals that the president was diagnosed with COVID-19 the day after the filmmakers finished editing. Now, in mid-October, even that fact feels like old news—the president certainly thinks it is. Yet as painful as examining the past in all its ugliness may be, it’s a necessary task. As Totally Under Control makes plain, there’s no clear ending in sight for Americans. But there won’t be an ending at all if lessons aren’t learned.

We want to hear what you think about this article. Submit a letter to the editor or write to letters@theatlantic.com.

https://www.theatlantic.com/culture/archive/2020/10/totally-under-control-essential-pandemic-documentary/616729/

Thursday, 2 July 2020

Germany has for now enough remdesivir for COVID-19 therapy: govt


BERLIN (Reuters) - Germany has secured enough supplies for now of remdesivir, which is set to become the first COVID-19 treatment approved in Europe, and is banking on developer Gilead to meet future needs, the country’s health ministry said on Wednesday.
JULY 1, 2020 / 6:28 PM / UPDATED 3 HOURS AGO
FILE PHOTO: A lab technicians holds the coronavirus disease (COVID-19) treatment drug "Remdesivir"
at Eva Pharma Facility in Cairo, Egypt June 25, 2020. REUTERS/Amr Abdallah Dalsh

The U.S. Department of Health and Human Services (HHS) this week said it had secured all of Gilead’s projected production for July and 90% of its production in August and September, in addition to an allocation for clinical trials.
“The federal government has early on secured remdesivir for the treatment of coronavirus patients. Currently, there are still sufficient reserves,” Germany’s health ministry told Reuters in a written statement.
With a conditional market approval, which is expected to be issued by the EU Commission this week, comes an obligation to deliver sufficient quantities in the future, it added.
“We trust Gilead will meet this obligation,” the ministry said.
Once supplies are less constrained, HHS will stop managing the allocation, Gilead said at the time of the department’s statement.
Gilead has linked up with generic drugmakers based in India and Pakistan to supply remdesivir in 127 developing countries, but it has not discussed its supply strategy for developed nations outside the United States.

Treatment drugs recommended so far:
ALSO:

Sunday, 14 June 2020

UK authorises anti-viral drug remdesivir - Coronavirus

A drug treatment called remdesivir that appears to shorten recovery time for people with coronavirus is being made available on the NHS.
  • 26 May 2020

Vials of remdesivir
Experts warn remdesivir shouldn't be seen as a "magic bullet"
Health Secretary Matt Hancock said it was probably the biggest step forward in the treatment of coronavirus since the crisis began.
Remdesivir is an anti-viral medicine that has been used against Ebola.
UK regulators say there is enough evidence to approve its use in selected Covid-19 hospital patients.
For the time being and due to limited supplies, it will go to those most likely to benefit.
The US and Japan have already made similar urgent arrangements to provide early access to the medicine before they have a marketing agreement.
The drug is currently undergoing clinical trials around the world, including in the UK.
Early data suggests it can cut recovery time by about four days, but there is no evidence yet that it will save more lives.
It is not clear how much stock pharmaceutical company Gilead Sciences has available to treat UK patients.
Allocation of the intravenous drug will be based on the advice of doctors.
Minister for Innovation Lord Bethell said: "This shows fantastic progress. As we navigate this unprecedented period, we must be on the front foot of the latest medical advancements, while always ensuring patient safety remains a top priority.
"The latest, expert scientific advice is at the heart of every decision we make, and we will continue to monitor remdesivir's success in clinical trials across the country to ensure the best results for UK patients."
Dr Stephen Griffin from the University of Leeds Medical School, said it was perhaps the most promising anti-viral for coronavirus so far.
He said patients with the most severe disease would be likely to receive it first. "Whilst this is clearly the most ethically sound approach, it also means that we ought not to expect the drug to immediately act as a magic bullet.
"We can instead hope for improved recovery rates and a reduction in patient mortality, which we hope will benefit as many patients as possible."
Other drugs being investigated for coronavirus include those for malaria and HIV.
Testing of the malaria drug hydroxychloroquine has been halted in some trials because of safety fears.
The World Health Organization says the temporary suspension is a precaution, after a recent medical study found the drug might increase the risk of death and heart rhythm complications.
In the UK, the Recovery trial looking at using this drug in patients remains open, but another one, using it in frontline NHS staff to prevent rather than treat infections, has paused recruiting more volunteers.

Banner image reading 'more about coronavirus'




More on this story


Other links:

Search Results

Web results

May 6, 2020 - TOKYO: Japan plans to authorise Thursday the antiviral drug remdesivir to treat coronavirus patients, the government said, with an eye to ...
Remdesivir is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences. It is administered via injection into a vein. As of 2020, remdesivir is being tested as a specific treatment for COVID-19, ... with promising antiviral activity" was performed by scientists at the Centers for ...

6 days ago - The US supply of the COVID-19 treatment remdesivir is on pace to run out at the end of June, the Department of Health and Human Services has ...
May 22, 2020 - ... emergency use of Gilead Sciences Inc's antiviral drug remdesivir to treat COVID-19, so they can direct limited supplies on the right patients.
4 days ago - Singapore approves Ebola drug remdesivir for treatment of coronavirus ... of Gilead Sciences Inc's antiviral drug remdesivir for the treatment of severely ill ... Download our free app on the App Store or Google Play for the latest ...
May 13, 2020 - Though remdesivir, a new treatment for COVID-19, has been hailed as a ... “NIAID statisticians performed modeling of what happens if the right ...

Apr 11, 2020 - Study sponsored by drug's developer Gilead finds dozens of patients, including some on ventilators, improved after 10 days of treatment.


May 21, 2020 - Remdesivir could be the first real treatment for COVID-19 that finally gives ... Whatever role remdesivir ends up playing in controlling COVID-19, ...
May 6, 2020 - Remdesivir doesn't cure coronavirus. But the experimental drug, which may speed up recovery from a COVID-19 infection, is currently the best ...
Apr 30, 2020 - Of the antiviral, antibiotic, antiretroviral and anti-malarial medicines being studied in trials to treat and prevent Covid-19, a drug called remdesivir ...
3 days ago - While only remdesivir has been scientifically shown to help treat COVID-19, it is not a particularly effective drug. More drugs like it and ...

Web results

Apr 30, 2020 - Preliminary results from a US trial show remdesivir may help in treating COVID-19. But the findings haven't been peer-reviewed, and the results ...
May 24, 2020 - Gilead Sciences Inc.'s remdesivir, the first medicine cleared for the treatment of Covid-19, mainly benefited healthier patients who weren't ...

May 1, 2020 - Remdesivir, an antiviral drug designed to treat both hepatitis and a ... and transformation testifies to the powerful role played by federal funding, ...

ALSO: